Please login to the form below

Not currently logged in
Email:
Password:

naloxone

This page shows the latest naloxone news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs Indivior’s drug to fight opioid addiction

FDA panel backs Indivior’s drug to fight opioid addiction

naloxone), another treatment for opioid dependence, and which raised the threat of low-cost copies reaching the market earlier than expected.

Latest news

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    N/D. AntiOp / Reckitt Benckiser. Supply and marketing agreement. Intranasal naloxone for opioid abuse in late clinical development.

  • Pharma deals during May 2014 Pharma deals during May 2014

    of alcohol abuse; and a supply and marketing agreement with AntiOp for intranasal naloxone for opioid abuse.

  • Pharma deals during November 2013 Pharma deals during November 2013

    The licence is for tamper resistant oxycodone (marketed in the US since 2010) and an oxycodone/naloxone combination marketed in Europe since 2009.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics